Comment
. 2001 Jul 24;57(2):369; author reply 369-70.
Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study
- PMID: 11480425
Item in Clipboard
Comment
Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study
Neurology.
.
No abstract available
Comment on
-
Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.Neurology. 1998 Sep;51(3):825-30. doi: 10.1212/wnl.51.3.825. Neurology. 1998. PMID: 9748034
-
Selegiline and Parkinson's disease: it's déjà vu-again.Neurology. 2000 Dec 26;55(12):1770-1. doi: 10.1212/wnl.55.12.1770. Neurology. 2000. PMID: 11134369 No abstract available.
-
Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study.Neurology. 2000 Dec 26;55(12):1785-9. doi: 10.1212/wnl.55.12.1785. Neurology. 2000. PMID: 11134373
Similar articles
-
Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study.Neurology. 2001 Jul 24;57(2):368-9; author reply 369-70. doi: 10.1212/wnl.57.2.368-a. Neurology. 2001. PMID: 11468339 No abstract available.
-
Deprenyl in Parkinson's disease.Ann Neurol. 1996 Aug;40(2):268-9. doi: 10.1002/ana.410400229. Ann Neurol. 1996. PMID: 8773617 No abstract available.
-
[Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].Rev Neurol (Paris). 1996 Feb;152(2):103-5. Rev Neurol (Paris). 1996. PMID: 8761616 French. No abstract available.
-
Current status of selegiline as a neuroprotective agent in Parkinson's disease.Mov Disord. 1998;13 Suppl 1:55-8. Mov Disord. 1998. PMID: 9613720 Review. No abstract available.
-
[Drug therapy of Parkinson's disease].Duodecim. 1997;113(18):1827-34. Duodecim. 1997. PMID: 10892076 Review. Finnish. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical